Clinical trials: Prurigo Nodularis
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN2 (NCT05764161)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 190 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis
Safety and Efficacy of CC-10004 for Prurigo Nodularis
This trial will include: Study period up to 7 months. Office visits monthly lasting approximately 1 hour. Blood Draws. Oral medication that is taken 2 times daily. Photographs and biopsies if agreed.
- Trial name
- NCT00869089
- Testing
- CC-10004
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University Hospitals Cleveland Medical Center
Prurigo Nodularis, Nodularis Prurigo
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
The primary objectives of the study are to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in patients with prurigo nodularis and to…
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
- Trial name
- NCT02174419
- Testing
- nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 62 people
- Sponsor
- Trevi Therapeutics
Neurodermatitis
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Primary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapy or when those therapies are not advisable.
- Trial name
- NCT04202679
- Testing
- Dupilumab SAR231893, Moisturizers, Low to medium potent topical corticosteroids
- Where
- 57 sites in United States, Canada and 9 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Prurigo Nodularis
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.
- Trial name
- NCT04501679
- Testing
- Nemolizumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 274 people
- Sponsor
- Galderma R&D
Prurigo Nodularis, Nodularis Prurigo
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo
- Trial name
- NCT02174432
- Testing
- nalbuphine HCl ER
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Trevi Therapeutics
Prurigo Nodularis
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
- Trial name
- NCT04501666
- Testing
- Nemolizumab 30 mg
- Where
- 100 sites in United States, Austria and 8 more
- Volunteers
- 286 people
- Sponsor
- Galderma R&D
Prurigo Nodularis, Pruritus
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
The primary objective is to assess the efficacy, safety, and tolerability of Abrocitinib for the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in patients experiencing moderate to severe…
- Conditions
- Prurigo Nodularis, Pruritus, Chronic Pruritus, Chronic Prurigo
- Trial name
- NCT05038982
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Prurigo Nodularis, Pruritis
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN).
- Trial name
- NCT03816891
- Testing
- Vixarelimab
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 240 people
- Sponsor
- Genentech, Inc.
Pruritus, Prurigo Nodularis
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
Study of the long term safety of serlopitant for the treatment of pruritus in adults.
- Conditions
- Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
- Trial name
- NCT03540160
- Testing
- 5 mg Serlopitant Tablets
- Where
- 85 sites in United States, Austria and 2 more
- Volunteers
- 558 people
- Sponsor
- Vyne Therapeutics Inc.
Neurodermatitis
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Primary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapies or when those therapies are not advisable.
- Trial name
- NCT04183335
- Testing
- Dupilumab SAR231893, Moisturizers, Low to medium potent topical corticosteroids
- Where
- 63 sites in United States, Argentina and 6 more
- Volunteers
- 151 people
- Sponsor
- Sanofi
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension…
- Trial name
- NCT05061693
- Testing
- INCB054707
- Where
- 49 sites in United States, Canada and 4 more
- Volunteers
- 146 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
- Trial name
- NCT02196324
- Testing
- serlopitant
- Where
- 15 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Vyne Therapeutics Inc.
Prurigo Nodularis
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
The main objective of this study is to assess the long-term durability of response over a 24-week period following withdrawal of nemolizumab in participants with prurigo nodularis (PN) who previously responded to treatment in the…
- Trial name
- NCT05052983
- Testing
- Nemolizumab
- Where
- 14 sites in United States, Austria and 5 more
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
Prurigo Nodularis
Safety and Efficacy of Nemolizumab in PN
The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.
- Trial name
- NCT03181503
- Testing
- CD14152 Dose A
- Where
- 16 sites in Austria, France and 2 more
- Volunteers
- 70 people
- Sponsor
- Galderma R&D
Prurigo Nodularis
PRISM Study-Pruritus Relief Through Itch Scratch Modulation
To investigate the anti-pruritic efficacy and safety of Nalbuphine Extended Release (ER) (NAL ER) tablets in Prurigo Nodularis. Participants were randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at…
- Trial name
- PRISM (NCT03497975)
- Testing
- Nalbuphine ER Tablets
- Where
- 70 sites in United States, Austria and 3 more
- Volunteers
- 353 people
- Sponsor
- Trevi Therapeutics
Prurigo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN1 (NCT05755438)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 71 sites in United States, Argentina and 9 more
- Volunteers
- 204 people
- Sponsor
- Incyte Corporation
Healthy Volunteers
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult…
- Trial name
- NCT05405985
- Testing
- Nemolizumab
- Where
- 2 sites in United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Pruritus, Prurigo Nodularis
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis
- Trial name
- NCT03546816
- Testing
- 5mg Serlopitant Tablets
- Where
- 49 sites in United States
- Volunteers
- 285 people
- Sponsor
- Vyne Therapeutics Inc.
Pruritus, Prurigo Nodularis
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis
- Trial name
- NCT03677401
- Testing
- 5mg Serlopitant Tablets
- Where
- 40 sites in Austria, Germany and 1 more
- Volunteers
- 295 people
- Sponsor
- Vyne Therapeutics Inc.